Unmodified autologous stem cells at point of care for chronic myocardial infarction

doi:10.4252/wjsc.v11.i10.831

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8663)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-14) series, Tables (1-2) series.

Item

Count

PDF

625

WORD

301

HTML

4507

Figures (1-14)

398

Tables (1-2)

262

Sum=6093

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

851

Download

1719

Sum=2570

Oct 26, 2019 (publication date) through Jan 31, 2025

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Stem Cells. Oct 26, 2019; 11(10): 831-858
Published online Oct 26, 2019. doi: 10.4252/wjsc.v11.i10.831

Full Size Figure Download Figure

Figure 7 Analysis of cell surface markers of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells from an animal in group 1 using flow cytometry. The cells were stained with monoclonal antibodies for CD29, CD44, NG2, Oct4, CD31, CD45, Nestin, CD146 and CD117 at passage 0. Flow cytometric histographs are representative of triplicate experiments.

Citation: Haenel A, Ghosn M, Karimi T, Vykoukal J, Shah D, Valderrabano M, Schulz DG, Raizner A, Schmitz C, Alt EU. Unmodified autologous stem cells at point of care for chronic myocardial infarction. World J Stem Cells 2019; 11(10): 831-858
URL: https://www.wjgnet.com/1948-0210/full/v11/i10/831.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i10.831